Executive Director, Medical and Scientific Writing
Annexon Biosciences
Executive Director, Medical and Scientific Writing
Annexon Biosciences
Develops C1q inhibitor therapies
Company:
At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Our novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, we are rigorously advancing our mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. At Annexon, you’ll be part of a team committed to making an impact together.
For more information on Annexon and our pipeline, check out our site Annexon Biosciences & Annexon Pipeline. We trade on Nasdaq under the ticker symbol ANNX and are headquartered in Brisbane, CA.
We're seeking exceptional talent from all backgrounds to fuel our growth. At Annexon, we're building a diverse, equitable, and inclusive workplace. We value unique perspectives and unconventional paths. If you're the best candidate for the job, even if you don't perfectly fit the traditional mold, we encourage you to apply. Learn more about our commitment to diversity, equity, inclusion, and our company culture!
Position:
The Executive Director, Medical and Scientific Writing provides strategic leadership and oversight of medical and scientific writing across the organization. Reporting to the SVP, Regulatory, Quality and Pharmacovigilance, you will work in partnership with a talented and collaborative team across our Clinical, Regulatory, Quality, Medical Affairs, Commercial and CMC departments to lead the strategy, authoring, and development of key documents in support of all of our programs. You will provide strategic direction in interpreting data, shaping scientific messaging, and overseeing the development of Clinical and Regulatory documents. This role will lead the development and ongoing optimization of critical writing infrastructure and processes at Annexon, including the development of best practices and resources for document management and timelines, template and shell creation, lexicon and document QC, publishing, and editing standards. You will also have an opportunity to support scientific communications, including the creation of manuscripts, abstracts and posters for congresses and external publication.
Responsibilities include:
Education, Experience, and Skills:
Required:
Salary Range: $286,000 - $314,600
Location: Annexon Biosciences is located in Brisbane, California This role operates under a hybrid work arrangement and requires regular onsite collaboration at our office. Candidates should be located within commuting distance and able to work in the office multiple days each week.
Benefits:
Annexon Biosciences is an Equal Opportunity Employer, and we prohibit discrimination or harassment of any kind. We are committed to fostering an environment where ALL people are welcome and supported. We cultivate a culture of inclusion for all employees that respects their individual strengths, views, and experiences. We believe that our differences enable us to be a better team – one that makes better decisions, drives innovation, and delivers better business results. Creativity and innovation flourish in an environment of openness, inclusion, and mutual respect.
Develops C1q inhibitor therapies
Annexon Biosciences develops therapies that target the classical complement pathway to treat autoimmune and neurodegenerative diseases, including eye conditions. Its main strategy is to inhibit C1q, the molecule that starts the complement cascade, with the aim of stopping disease progression at its source. The company advances therapies through clinical trials and may either commercialize them or partner with larger pharma firms to bring them to market. Revenue potential comes from product sales, licensing, and milestone payments from collaborations. Annexon’s goal is to deliver first-in-class C1q inhibitors that prevent tissue damage across diseases such as Alzheimer's, Huntington's, glaucoma, and related disorders, supported by substantial financing to push its pipeline forward.
Explore more opportunities at Annexon Biosciences